Christopher J. Hasenberg Inc Takes Position in Eli Lilly and Company (NYSE:LLY)

Christopher J. Hasenberg Inc acquired a new position in shares of Eli Lilly and Company (NYSE:LLY) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 870 shares of the company’s stock, valued at approximately $507,000. Eli Lilly and Company makes up about 0.3% of Christopher J. Hasenberg Inc’s holdings, making the stock its 17th largest position.

A number of other institutional investors have also recently added to or reduced their stakes in LLY. Vanguard Group Inc. raised its stake in shares of Eli Lilly and Company by 0.9% during the 3rd quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock worth $37,908,273,000 after buying an additional 659,838 shares during the last quarter. Morgan Stanley lifted its holdings in shares of Eli Lilly and Company by 0.7% in the third quarter. Morgan Stanley now owns 12,545,572 shares of the company’s stock valued at $6,738,605,000 after purchasing an additional 83,915 shares in the last quarter. Norges Bank acquired a new stake in shares of Eli Lilly and Company in the fourth quarter valued at approximately $5,992,890,000. Northern Trust Corp grew its position in shares of Eli Lilly and Company by 3.6% in the third quarter. Northern Trust Corp now owns 10,158,275 shares of the company’s stock valued at $5,456,314,000 after purchasing an additional 355,317 shares during the last quarter. Finally, International Assets Investment Management LLC increased its stake in shares of Eli Lilly and Company by 61,268.8% during the 4th quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company’s stock worth $42,802,530,000 after purchasing an additional 7,330,815 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 0.5 %

NYSE LLY traded up $3.82 during mid-day trading on Monday, hitting $737.33. The company’s stock had a trading volume of 2,726,536 shares, compared to its average volume of 3,017,770. The firm has a market capitalization of $700.58 billion, a P/E ratio of 127.13, a price-to-earnings-growth ratio of 1.60 and a beta of 0.34. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73. Eli Lilly and Company has a 52-week low of $392.26 and a 52-week high of $800.78. The stock’s fifty day simple moving average is $760.89 and its two-hundred day simple moving average is $668.00.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The business had revenue of $9.35 billion for the quarter, compared to the consensus estimate of $8.95 billion. During the same quarter last year, the firm posted $2.09 EPS. The business’s revenue for the quarter was up 28.1% compared to the same quarter last year. Research analysts expect that Eli Lilly and Company will post 12.51 EPS for the current year.

Analysts Set New Price Targets

LLY has been the topic of a number of analyst reports. Bank of America increased their target price on Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a report on Friday, March 1st. Cantor Fitzgerald reiterated an “overweight” rating and set a $815.00 price objective on shares of Eli Lilly and Company in a research report on Monday, April 15th. BMO Capital Markets upped their target price on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a report on Wednesday, February 7th. Barclays lifted their price target on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a report on Wednesday, February 7th. Finally, Wells Fargo & Company upped their price objective on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a research note on Tuesday, February 6th. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $728.05.

Insider Transactions at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 78,573 shares of Eli Lilly and Company stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the sale, the insider now owns 99,333,810 shares in the company, valued at $64,375,262,246.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.13% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.